Oxitropium

Also used as a comparator or background therapy in 4 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 32 trials
Phase 3	NCT02172807 Comparator	Dec 2000 → Sep 2001	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172430 Comparator	Sep 2000 → May 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase not applicable2 trials
—	NCT02509299 Background	Sep → Nov 2019	chronic obstructive pulmonary disease	University of Granada	Completed	No outcome recorded
—	NCT02515318 Comparator	Sep 2015 → Mar 2017	chronic obstructive pulmonary disease	University of Granada	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 5 sources stand behind the page.

Field	Value	Cited text
Known as	Oxitropium	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02172807 ↗
Known as	BA-253	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297364 ↗
Known as	Bromure d'oxitropium	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297364 ↗
Known as	Bromuro de oxitropio	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297364 ↗
Known as	oxitropium bromide	“anticholinergic agents (ipratropium and oxitropium bromide)” NCT02515318 ↗ 2 “anticholinergic agents (ipratropium and oxitropium bromide)” NCT02509299 ↗ “using oxitropium bromide (Tersigan) as a comparator” NCT02172430 ↗
Known as	Oxivent	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297364 ↗
Known as	Tersigan	“using oxitropium bromide (Tersigan) as a comparator” NCT02172430 ↗
Modality	Small molecule	— CHEMBL4297364 ↗
Route	Inhaled	“2 puffs of oxitropium three times daily via MDI” NCT02172430 ↗